New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
13:55 EDTPFE, PFE, PTIE, PTIE, DRRX, DRRX, ENDP, ENDPSummer Street's biotech research team holds an analyst/industry conference call
Biotech Analyst Research Team discusses Remoxy on an Analyst/Industry conference call to be held on January 28 at 2:30 pm.
News For PFE;PTIE;DRRX;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 2, 2015
07:15 EDTENDPEndo sees FY15 adjusted EPS ex-AMS $4.35-$4.55, consensus $4.88
Subscribe for More Information
07:11 EDTENDPEndo reports Q4 adjusted EPS $1.16, consensus $1.12
Reports Q4 revenue $799.96M, consensus $780.44M.
07:10 EDTENDPEndo to sell AMS urology portfolio to Boston Scientific for up to $1.65B
Boston Scientific (BSX) announced that it has entered into a definitive agreement with Endo International (ENDP) to acquire the American Medical Systems' urology portfolio, which includes the Men's Health and Prostate Health businesses, for $1.6B in up-front cash and a potential additional $50M milestone based on 2016 sales. The company expects to close the transaction in the third quarter of 2015, subject to customary closing conditions. Upon completion of the transaction, the AMS Men's Health and Prostate Health businesses will become part of Boston Scientific Urology and Women's Health. The acquisition encompasses the AMS product portfolio for treating urologic conditions, including benign prostatic hyperplasia, male stress urinary incontinence and erectile dysfunction. These technologies complement Boston Scientific's strong kidney stone, pelvic organ prolapse, female stress urinary incontinence and abnormal uterine bleeding treatment portfolios, and together, will provide customers with a comprehensive urology, urogynecology and gynecologic surgery portfolio. The AMS women's health business for treating pelvic organ prolapse and female stress urinary incontinence is not included in the transaction. The AMS Men's Health and Prostate Health businesses generated 2014 sales of approximately $400M and adjusted operating income of approximately $130M, excluding amortization and certain allocated expenses. GAAP operating income, including amortization and certain allocated expenses, was approximately $60M in 2014. The acquisition is expected to result in annual pre-tax synergies in excess of $50M by the end of 2018. On an adjusted basis, the transaction is expected to be breakeven to adjusted earnings per share in 2015, accretive by at least 3c in 2016, approximately 7c in 2017, and increasingly accretive thereafter. The transaction is expected to be less accretive, or dilutive, as the case may be, on a GAAP basis 2015 through 2017, due to amortization expense and transaction and integration costs. The acquisition is being structured as an asset purchase for tax purposes. Boston Scientific intends to finance the acquisition through a combination of existing and newly committed credit facilities.
07:08 EDTENDPEndo to sell AMS urology portfolio to Boston Scientific for up to $1.65B
Subscribe for More Information
07:08 EDTENDPBoston Scientific enters $1.65B agreement with Endo to acquire urology portfolio
Subscribe for More Information
February 26, 2015
12:31 EDTPFEPfizer says CDC recommends serogroup B meningococcal vaccine for those at risk
Subscribe for More Information
07:33 EDTENDPQLT Inc. reports Q4 EPS 31c, consensus 14c
Subscribe for More Information
February 24, 2015
14:31 EDTENDPBoston Scientific deal for Endo unit would be favorably received, says Needham
Subscribe for More Information
12:40 EDTENDPBoston Scientific may strike deal for Endo AMS unit within weeks, Reuters says
Boston Scientific (BSX) is reportedly close to buying Endo International's (ENDP) AMS medical device unit which could be valued at roughly $2B, reports Reuters, citing people familiar with the matter. The sources said the companies want to finalize a deal "within a matter of weeks" but cautioned that talks are continuing and could still fail. Reference Link
12:14 EDTENDPEndo near deal to sell AMS device unit to Boston Scientific, Reuters says
08:07 EDTPFEPfizer announces Trumenba studies met primary objectives
Subscribe for More Information
February 23, 2015
12:53 EDTENDPAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
09:02 EDTENDPAcceptance of NDA for Belbuca triggers $10M milestone payment to BDSI
Subscribe for More Information
07:31 EDTENDPEndo, BioDelivery Sciences announce acceptance of NDA for Belbuca
Subscribe for More Information
February 22, 2015
15:59 EDTENDPValeant to buy Salix for $10.1B, FT says
Subscribe for More Information
February 20, 2015
10:33 EDTPFEBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
10:31 EDTPFEPfizer announces FDA acceptance of NDA for Rapamune
Pfizer announced that the FDA has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. With the Priority Review designation for the sNDA, Pfizer anticipates a decision in June of 2015 based on the anticipated Prescription Drug User Fee Act action date. The sNDA is based on results from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial. The MILES Trial included 89 LAM patients with moderate lung impairment who were randomized to receive RAPAMUNE or placebo for 12 months, followed by a 12 month observation period. In the trial, those treated with RAPAMUNE for one year experienced stabilization of lung function as measured by forced expiratory volume in one second.
09:17 EDTENDPEndo price target raised to $101 from $86 at Goldman
Subscribe for More Information
08:21 EDTENDPSummer Street still feels Endo could acquire BioDelivery Sciences
Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.
07:23 EDTPFEAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use